Warning! GuruFocus detected
2 Severe warning signs
with AKP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Anika Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US0352551081
Share Class Description:
FRA:AKP: Ordinary SharesDescription
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.15 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 8.59 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.02 | |||||
| Beneish M-Score | -3.94 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.9 | |||||
| 3-Year Book Growth Rate | -18.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.97 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 10.42 | |||||
| 9-Day RSI | 15.88 | |||||
| 14-Day RSI | 20.62 | |||||
| 3-1 Month Momentum % | 3.97 | |||||
| 6-1 Month Momentum % | -31.14 | |||||
| 12-1 Month Momentum % | -34.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.88 | |||||
| Quick Ratio | 3.85 | |||||
| Cash Ratio | 2.39 | |||||
| Days Inventory | 313.78 | |||||
| Days Sales Outstanding | 87.77 | |||||
| Days Payable | 64.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 | |||||
| Shareholder Yield % | 6.42 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 63.38 | |||||
| Operating Margin % | -4.25 | |||||
| Net Margin % | -47.02 | |||||
| FCF Margin % | -2.54 | |||||
| ROE % | -29.22 | |||||
| ROA % | -22.9 | |||||
| ROIC % | -9.57 | |||||
| 3-Year ROIIC % | -15.03 | |||||
| ROC (Joel Greenblatt) % | -4.01 | |||||
| ROCE % | -2.33 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 186.42 | |||||
| PS Ratio | 1.64 | |||||
| PB Ratio | 1.25 | |||||
| Price-to-Tangible-Book | 1.33 | |||||
| Price-to-Operating-Cash-Flow | 36.31 | |||||
| EV-to-EBIT | -33.05 | |||||
| EV-to-Forward-EBIT | -23.79 | |||||
| EV-to-EBITDA | 55.81 | |||||
| EV-to-Forward-EBITDA | 40.75 | |||||
| EV-to-Revenue | 1.41 | |||||
| EV-to-Forward-Revenue | 1.49 | |||||
| EV-to-FCF | -57.58 | |||||
| Price-to-GF-Value | 0.58 | |||||
| Price-to-Projected-FCF | 1.01 | |||||
| Price-to-Median-PS-Value | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 2.97 | |||||
| Price-to-Net-Cash | 28 | |||||
| Earnings Yield (Greenblatt) % | -3.02 | |||||
| FCF Yield % | -1.48 | |||||
| Forward Rate of Return (Yacktman) % | -5.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anika Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 109.91 | ||
| EPS (TTM) (€) | -3.556 | ||
| Beta | 0.43 | ||
| 3-Year Sharpe Ratio | -0.4 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 35.65 | ||
| 14-Day RSI | 20.62 | ||
| 14-Day ATR (€) | 0.273701 | ||
| 20-Day SMA (€) | 14.25 | ||
| 12-1 Month Momentum % | -34.58 | ||
| 52-Week Range (€) | 12.6 - 26.4 | ||
| Shares Outstanding (Mil) | 14.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anika Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anika Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anika Therapeutics Inc Frequently Asked Questions
What is Anika Therapeutics Inc(FRA:AKP)'s stock price today?
The current price of FRA:AKP is €12.60. The 52 week high of FRA:AKP is €26.40 and 52 week low is €12.60.
When is next earnings date of Anika Therapeutics Inc(FRA:AKP)?
The next earnings date of Anika Therapeutics Inc(FRA:AKP) is 2025-05-08 Est..
Does Anika Therapeutics Inc(FRA:AKP) pay dividends? If so, how much?
Anika Therapeutics Inc(FRA:AKP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers